Lisata Therapeutics, a clinical-stage pharmaceutical company, is undergoing a significant digital transformation focused on accelerating drug discovery and enhancing clinical trial capabilities. This involves integrating advanced artificial intelligence (AI) platforms and specialized data analytics tools into their research and development (R&D) workflows. The company's specific approach emphasizes leveraging external partnerships to access cutting-edge technologies, thereby streamlining the complex processes of identifying new therapeutic candidates and evaluating their efficacy in clinical studies.
This transformation creates critical dependencies on robust data pipelines, secure information systems, and seamless integration with external technology platforms. Challenges arise from ensuring data consistency, maintaining regulatory compliance across diverse data sources, and managing intellectual property generated through these collaborations. This page analyzes Lisata Therapeutics' key digital initiatives, highlights associated operational challenges, and identifies strategic sales opportunities.
Lisata Therapeutics Snapshot
Headquarters: Basking Ridge, New Jersey, United States
Number of employees: 21
Public or private: Public
Business model: B2B
Website: http://www.lisata.com
Lisata Therapeutics ICP and Buying Roles
Lisata Therapeutics sells to complex research institutions and specialized pharmaceutical development firms.
Who drives buying decisions
- Chief Medical Officer → Clinical trial design and execution oversight
- Executive Vice President of R&D → Research strategy and technology adoption
- Chief Information Officer and Data Protection Officer → Data governance and system security
- Vice President, Global Regulatory Affairs → Regulatory submission compliance and data integrity
Key Digital Transformation Initiatives at Lisata Therapeutics (At a Glance)
- Integrating AI into drug discovery: Utilizing GATC Health's MAT platform for predictive analytics in drug development.
- Analyzing clinical trial data: Deploying Haystack MRD™ technology for ctDNA detection in oncology studies.
- Managing regulatory document lifecycle: Standardizing processes for clinical trial data and submission artifacts.
- Centralizing research data platforms: Consolidating R&D data from internal and partner sources for analysis.
Where Lisata Therapeutics’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| AI/ML Platforms & Solutions | Integrating AI into drug discovery: AI-generated predictions require validation against preclinical and clinical data. | Executive Vice President of R&D, Chief Medical Officer | Validate AI model outputs for accuracy and biological relevance before drug candidate progression. |
| Integrating AI into drug discovery: proprietary data streams fail to integrate directly into external AI platforms. | Chief Information Officer and Data Protection Officer, Executive Vice President of R&D | Route secure data transfer protocols for sensitive research data to external AI systems. | |
| Integrating AI into drug discovery: lack of traceable audit trails for AI model decision-making impacts regulatory submissions. | Vice President, Global Regulatory Affairs | Enforce transparency and explainability in AI model outputs for compliance purposes. | |
| Clinical Data Management Platforms | Analyzing clinical trial data: disparate patient data sources create data ingestion delays into CDMS. | Chief Medical Officer, Executive Vice President of R&D | Standardize data formats from clinical sites and CROs before entry into central systems. |
| Analyzing clinical trial data: ctDNA data streams from external labs do not auto-populate into electronic data capture (EDC) systems. | Chief Medical Officer, Chief Information Officer and Data Protection Officer | Enforce automated integration of specialized biomarker data into core clinical platforms. | |
| Analyzing clinical trial data: inconsistent data definitions between study sites prevent consolidated reporting on trial progress. | Chief Medical Officer, Executive Vice President of R&D | Validate metadata schemas for uniform data interpretation across all clinical trial data. | |
| Regulatory & Compliance Systems | Managing regulatory document lifecycle: manual document version control creates errors in submission packages. | Vice President, Global Regulatory Affairs | Standardize document control workflows across regulatory teams before final assembly. |
| Managing regulatory document lifecycle: missing metadata in regulatory documents blocks automated content review for compliance. | Vice President, Global Regulatory Affairs | Detect and flag incomplete metadata fields in regulatory submissions before internal review. | |
| Data Integration & Orchestration | Centralizing research data platforms: research data from partner labs do not conform to internal data models. | Executive Vice President of R&D, Chief Information Officer and Data Protection Officer | Standardize external research data for ingestion into internal analytics platforms. |
| Centralizing research data platforms: fragmented research datasets hinder comprehensive analysis across drug candidates. | Executive Vice President of R&D, Chief Information Officer and Data Protection Officer | Enforce unified data models for all R&D data to enable cross-program comparisons. | |
| Centralizing research data platforms: data transfer failures occur between internal R&D systems and cloud-based analytics tools. | Chief Information Officer and Data Protection Officer | Detect and log data transfer anomalies between on-premise and cloud infrastructure. |
Identify when companies like Lisata Therapeutics are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Lisata Therapeutics’s digital transformation unique
Lisata Therapeutics prioritizes external technology partnerships to drive its digital transformation, specifically integrating advanced AI for drug discovery and specialized diagnostic data for clinical trials. This approach reduces the need for extensive in-house development of foundational AI models or complex biomarker analysis tools. The company heavily depends on robust data exchange capabilities and seamless integration with third-party platforms to convert external scientific advancements into internal R&D progress. This strategy makes their transformation more complex in terms of data governance, intellectual property management, and ensuring compatibility across diverse vendor ecosystems.
Lisata Therapeutics’s Digital Transformation: Operational Breakdown
DT Initiative 1: Integrating AI into drug discovery
What the company is doing
Lisata Therapeutics leverages GATC Health's Multiomics Advanced Technology (MAT) platform to apply artificial intelligence in the drug discovery process. This system predicts combination therapies and evaluates drug candidates for efficacy, safety, and potential side effects. The company also uses this platform to identify new therapeutic agents for various diseases.
Who owns this
- Executive Vice President of R&D
- Chief Medical Officer
- Chief Information Officer and Data Protection Officer
Where It Fails
- AI-generated therapeutic predictions do not always align with preclinical or clinical observations before drug candidate selection.
- Proprietary research data fails to map consistently into the external AI platform's data schemas for analysis.
- Lack of clear documentation on AI model inputs and outputs creates delays during intellectual property filing processes.
- New AI-identified drug targets do not automatically propagate into existing R&D project management systems for tracking.
Talk track
Noticed Lisata Therapeutics is integrating AI into its drug discovery workflows. Been looking at how some pharmaceutical teams are isolating AI predictions that contradict initial hypotheses for further human review, can share what’s working if useful.
DT Initiative 2: Analyzing clinical trial data
What the company is doing
Lisata Therapeutics deploys Haystack MRD™ technology in clinical studies to detect circulating tumor DNA (ctDNA) for pancreatic cancer. This initiative involves integrating specialized biomarker data to analyze the early therapeutic effect of drug candidates. This system enhances the assessment of treatment efficacy during active clinical trials.
Who owns this
- Chief Medical Officer
- Executive Vice President of R&D
- Chief Information Officer and Data Protection Officer
Where It Fails
- ctDNA data from external laboratory systems fails to synchronize automatically with the central clinical data management system.
- Inconsistent patient identification numbers create mismatches between ctDNA results and existing clinical records.
- Reporting tools do not aggregate ctDNA analysis with other patient data points for comprehensive efficacy assessments.
- Manual data reconciliation is required when ctDNA results conflict with other primary clinical endpoints.
Talk track
Saw Lisata Therapeutics is analyzing clinical trial data with advanced ctDNA technology. Been looking at how some oncology teams are enforcing data quality checks on biomarker uploads instead of manual validation, happy to share what we’re seeing.
DT Initiative 3: Data Governance & Cybersecurity for R&D and Clinical Data
What the company is doing
Lisata Therapeutics establishes robust internal controls for managing sensitive research and clinical trial information across its operations. This involves overseeing data access, ensuring data privacy, and implementing cybersecurity measures to protect intellectual property and patient data. This system supports compliance with regulations like GDPR and HIPAA.
Who owns this
- Chief Information Officer and Data Protection Officer
- Vice President, Global Regulatory Affairs
- Executive Vice President of R&D
Where It Fails
- Access permissions for sensitive R&D data are not consistently enforced across collaborative platforms.
- Audit trails for patient data access do not capture full user activity within the clinical trial management system.
- Automated alerts fail to trigger when unauthorized data transfer attempts occur from internal research databases.
- Data retention policies are not uniformly applied across all R&D and clinical data repositories.
Talk track
Looks like Lisata Therapeutics is strengthening data governance for R&D and clinical data. Been seeing teams enforce automated data classification to control access instead of manual tagging, can share what’s working if useful.
DT Initiative 4: Centralizing Research Data Platforms
What the company is doing
Lisata Therapeutics integrates research data from internal R&D activities and external partnerships into unified data platforms. This system consolidates diverse scientific information to support comprehensive analysis for drug development and to manage ongoing collaborations. This creates a central repository for all drug discovery related information.
Who owns this
- Executive Vice President of R&D
- Chief Information Officer and Data Protection Officer
- Head of Data Science (inferred)
Where It Fails
- Research data from different scientific instruments fails to ingest into the central platform in a standardized format.
- Data duplicates accumulate in the central platform due to inconsistent merging of information from external partners.
- Search functionality within the central platform does not retrieve all relevant research assets based on metadata tags.
- Changes to data schema from external collaborators break existing integration pipelines into the central platform.
Talk track
Noticed Lisata Therapeutics is centralizing its research data platforms. Been looking at how some biotech teams are standardizing data dictionaries upfront instead of post-ingestion clean-up, happy to share what we’re seeing.
Who Should Target Lisata Therapeutics Right Now
This account is relevant for:
- AI-driven drug discovery platforms
- Clinical trial data integration and analytics solutions
- Regulatory information management systems
- Data governance and security platforms
- R&D data management and collaboration tools
- Biomarker data analysis and reporting platforms
Not a fit for:
- Generic marketing automation tools
- Basic HR management software
- Standalone finance and accounting systems without R&D focus
- General IT infrastructure providers without biotech specialization
When Lisata Therapeutics Is Worth Prioritizing
Prioritize if:
- You sell solutions that validate AI-generated drug predictions against biological evidence.
- You sell platforms that integrate specialized biomarker data directly into clinical trial management systems.
- You sell tools that enforce data access controls and audit trails for sensitive R&D and patient information.
- You sell systems that standardize and consolidate diverse research data from multiple sources into a unified platform.
- You sell regulatory solutions that automate document version control and metadata tagging for submissions.
Deprioritize if:
- Your solution does not address specific data integration, validation, or security challenges within pharmaceutical R&D or clinical trials.
- Your product is limited to general business operations without specialized features for biotech industry compliance.
- Your offering does not support multi-party data collaboration and intellectual property protection.
Who Can Sell to Lisata Therapeutics Right Now
AI Model Validation & Governance Platforms
GATC Health - This company offers an AI-powered Multiomics Advanced Technology (MAT) platform that identifies drug candidates and predicts efficacy, safety, and side effects.
Why they are relevant: Lisata Therapeutics is already collaborating with GATC Health to integrate AI into their drug discovery. Failures occur when AI-generated predictions require further validation or when proprietary data needs secure integration. GATC Health's continued partnership and platform directly address the need for robust AI insights and seamless data exchange for drug development.
BenevolentAI - This company uses AI and machine learning to discover new drugs and accelerate drug development.
Why they are relevant: Lisata Therapeutics integrates AI into drug discovery, where AI-generated predictions need validation. BenevolentAI's focus on AI-driven drug discovery means they possess tools for model explainability and robust validation, crucial for regulatory compliance and R&D confidence.
Clinical Data Integration & Analytics Solutions
Medidata Solutions (Dassault Systèmes) - This company provides cloud-based solutions for clinical development, including electronic data capture (EDC), clinical trial management systems (CTMS), and clinical analytics.
Why they are relevant: Lisata Therapeutics integrates specialized ctDNA data into clinical studies. Failures arise from disparate data sources and inconsistent data definitions. Medidata's comprehensive platform can standardize data ingestion, provide integrated analytics for biomarker data, and ensure data consistency across multiple clinical sites.
Haystack Oncology - This company provides highly sensitive ctDNA detection technology for measuring minimal residual disease in oncology.
Why they are relevant: Lisata Therapeutics is collaborating with Haystack Oncology to deploy their MRD technology in clinical trials. Inconsistent data formats and lack of automated integration for ctDNA data cause failures. Haystack Oncology's direct involvement highlights the need for specialized tools that ensure accurate and timely integration of their unique biomarker data into Lisata's clinical systems.
Data Governance & Cybersecurity Platforms
Veeva Systems - This company provides cloud-based software for the global life sciences industry, including regulatory, quality, and clinical data management solutions.
Why they are relevant: Lisata Therapeutics focuses on data governance and cybersecurity for sensitive R&D and clinical data, where access permissions and audit trails often fail. Veeva's specialized platforms for life sciences enforce rigorous data access controls, track user activity, and ensure compliance with industry-specific data privacy regulations.
Datavant - This company provides a health data ecosystem that connects de-identified patient data for research and analytics while maintaining privacy.
Why they are relevant: Lisata Therapeutics handles sensitive R&D and clinical data, risking unauthorized data transfers. Datavant's solutions enable secure, de-identified data sharing, preventing breaches during collaboration with external partners and ensuring adherence to strict data protection regulations.
Final Take
Lisata Therapeutics scales its drug discovery pipeline by embedding AI and integrating advanced clinical biomarker data, creating dependencies on external technology partnerships and robust data systems. Breakdowns are visible in data validation for AI predictions, seamless integration of specialized clinical data, and consistent data governance across sensitive R&D information. This account is a strong fit for vendors offering solutions that specifically address data integrity, system interoperability, and compliance challenges within complex pharmaceutical R&D and clinical trial environments.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.